Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Standard AI models trained on public, observational biological data excel at descriptive tasks but underperform even linear models on causal predictions. To predict cellular responses to drug-like perturbations, models must be trained specifically on causal data generated from targeted experiments.
Related Insights
In developing the X-Cell model, Xaira found a clear hierarchy of impact. The quality, scale, and causal nature of the training data provided the most significant performance boost, followed by the choice of AI architecture (e.g., diffusion vs. autoregressive), and lastly, the integration of prior biological knowledge.
Public datasets primarily show successful protein interactions, starving AI models of crucial "negative data"鈥攑lausible but incorrect interactions. A-Alpha Bio finds that providing this data on what fails is just as important for training predictive and generalizable models.
To create a predictive "virtual cell," data collection must shift from passive observation to active intervention. The strategy is to massively scale perturbation experiments (like Perturb-seq) across countless contexts and measure multi-modal responses, teaching the model cause and effect.
Today's "virtual cell" models represent training data well but cannot predict outcomes for novel interventions. The next frontier is building models that generalize to serve as true predictive oracles for experiments that haven't yet been performed, a key focus for BioHub.
AI models trained on descriptive data (e.g., RNA-seq) can classify cell states but fail to predict how to transition a diseased cell to a healthy one. True progress requires generating massive "causal" datasets that show the effects of specific genetic perturbations.
The primary obstacle to creating sophisticated AI models of cells isn't the AI itself, but the data. Existing datasets often perturb only one cellular variable at a time, failing to capture the complex interactions that arise from simultaneous changes. New platforms are needed to generate this multi-dimensional data.
The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.
Achieving explainability in AI for drug development isn't about post-hoc analysis. It requires building models from the ground up using inherently interpretable data like RNA sequencing and mutational profiles. When the inputs are explainable, the model's outputs become explainable by design.
While petabytes of observational DNA sequence data exist, it's insufficient for the next wave of AI. The key to creating powerful, functional models is generating causal data鈥攆rom experiments that systematically test function鈥攚hich is a current data bottleneck.
The key utility of a "virtual cell" model isn't just predicting outcomes within its training data. Its power is the ability to generalize and make accurate causal predictions in entirely new contexts, such as different cell types or primary cells from donors, where large-scale experiments are difficult or impossible.